Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management

A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial

The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.

Inclusion Criteria:

• Age 18 and more
• Index event of non-ST or ST segment elevation ACS
• Provision of signed informed consent

Exclusion Criteria:

• Hypersensitivity to aspirin or ticagrelor
• Oral anticoagulation therapy that cannot be stopped
• Treated with thrombolysis within 24hrs
• Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
• Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
• Any life-threatening condition with life expectancy less than 6months
• Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
• High risk due to malignant hypertension
• The conditions associated with increased risk of bradycardiac events
• Subjects with severe liver disease
• Subjects requiring dialysis
• Increased bleeding risk
• History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
• Thrombocytopenia or leukopenia
• Positive pregnancy test or is known to be pregnant